- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07232069
전향적 무작위 평가 및 조기 죽상경화증 관리(PRE-EMPT) (PRE-EMPT)
전향성 무작위 대조군 연구를 통한 조기 동맥경화증의 평가 및 치료
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
-
A Screening Study - Participants will be assessed for plaque by one or both of these scans.
- Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
- Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
-
A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
- Rosuvastatin 20 mg: a cholesterol-lowering medicine
- Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
연구 개요
상태
상세 설명
The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Rachel Olson, Project Manager
- 전화번호: 919-309-5544
- 이메일: rachel.e.olson@duke.edu
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35205
- 모병
- University of Alabama at Birmingham
-
수석 연구원:
- Kevin Riggs, MD
-
연락하다:
- Dalton Norwood
- 전화번호: 909-786-8315
- 이메일: daltonnorwood@uabmc.edu
-
Mobile, Alabama, 미국, 36608
- 모병
- Cardiology Associates
-
연락하다:
- Lynn Ward, RN BSN CCRC
- 전화번호: 251-607-9797
- 이메일: lynnward@cardassoc.com
-
수석 연구원:
- Jason Cole, MD
-
-
California
-
Los Angeles, California, 미국, 90095
- 모병
- University of California, Los Angeles
-
연락하다:
- Lynae Edmunds
- 전화번호: 310--210-9806
- 이메일: laedmunds@mednet.ucla.edu
-
수석 연구원:
- Karol Watson, MD
-
Los Angeles, California, 미국, 90502
- 모병
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
-
연락하다:
- Sajad Hamal
- 전화번호: 310-974-9336
- 이메일: shamal@lundquist.org
-
수석 연구원:
- Matthew Budoff, MD
-
-
Georgia
-
Hiram, Georgia, 미국, 30141
- 모병
- Wellstar Kennestone Hospital
-
수석 연구원:
- Frank Corrigan, MD
-
연락하다:
- Frank Corrigan, MD
- 전화번호: 678-324-4444
- 이메일: frank.corrigan@wellstar.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago
-
수석 연구원:
- Tamar Polonsky, MD
-
연락하다:
- Tamar Polonsky, MD
- 전화번호: 773-702-1409
- 이메일: tpolonsky@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 아직 모집하지 않음
- Johns Hopkins University
-
연락하다:
- Prati Pratishruti, MBBS
- 전화번호: 410-301-1245
- 이메일: fpratis1@jhu.edu
-
수석 연구원:
- Michael Blaha, MD
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital Brigham
-
연락하다:
- Pearl Lee, MSc
- 전화번호: 617-721-7783
- 이메일: plee23@mgh.harvard.edu
-
수석 연구원:
- Michael Honigberg, MD
-
-
Minnesota
-
Duluth, Minnesota, 미국, 55805
- 모병
- Essentia Health
-
연락하다:
- Martha Vanderlinde, BS
- 전화번호: 218-786-2729
- 이메일: Martha.Vanderlinde@essentiahealth.org
-
수석 연구원:
- Catherine Benzinger, MD
-
-
New York
-
Mount Kisco, New York, 미국, 10549
- 아직 모집하지 않음
- Northern Westchester Hospital
-
연락하다:
- Dina Katz, MD
- 전화번호: 914-762-5810
- 이메일: PRE-EMPT@northwell.edu
-
수석 연구원:
- Dina Katz, MD
-
New York, New York, 미국, 10021
- 모병
- Weill Cornell Medicine
-
연락하다:
- Dolores Reynolds, RN
- 전화번호: 212-746-4617
- 이메일: dtr2001@med.cornell.edu
-
수석 연구원:
- Sam Kim, MD
-
New York, New York, 미국, 10016
- 모병
- New York University Langone
-
수석 연구원:
- Harmony Reynolds, MD
-
연락하다:
- Harmony Reynolds, MD
- 전화번호: 212-263-4320
- 이메일: PREEMPT@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Hospital
-
수석 연구원:
- Nishant Shah, MD
-
연락하다:
- Niki Huffman
- 전화번호: 919-681-6458
- 이메일: niki.huffman@duke.edu
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Wake Forest University, Advocate Health
-
수석 연구원:
- Michael Shapiro, MD
-
연락하다:
- Sophia Dawson, BA
- 전화번호: 336-713-2338
- 이메일: Sophia.Dawson@advocatehealth.org
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 아직 모집하지 않음
- Oregon Health and Sciences University
-
연락하다:
- John Halvorson
- 전화번호: 503-418-1679
- 이메일: halvorsj@ohsu.edu
-
수석 연구원:
- Maros Ferencik, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- 아직 모집하지 않음
- Thomas Jefferson University
-
연락하다:
- Caroline Freeman, BS
- 전화번호: 215-792-3872
- 이메일: Caroline.Freeman@Jefferson.edu
-
수석 연구원:
- Chris Chambers, MD
-
Pittsburgh, Pennsylvania, 미국, 15213
- 모병
- University of Pittsburgh Medical Center
-
수석 연구원:
- Anum Saeed, MD
-
연락하다:
- Karli Drewencki
- 전화번호: 412-647-2931
- 이메일: drewenckikr2@upmc.edu
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina (MUSC)
-
수석 연구원:
- Sheldon Litwin, MD
-
연락하다:
- Melissa Amitrano, MPH
- 전화번호: 843-876-5009
- 이메일: amitrano@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 아직 모집하지 않음
- Vanderbilt University
-
수석 연구원:
- Deepak Gupta, MD
-
연락하다:
- Gabriella Davies Thoppil, MD MPH
- 전화번호: 615-421-1143
- 이메일: g.thoppil@vumc.org
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- Houston Methodist Hospital
-
연락하다:
- Peyton Martin
- 전화번호: 443-413-6350
- 이메일: knasir@houstonmethodist.org
-
수석 연구원:
- Khurrrram Nasir, MD
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- 모병
- University of Virginia (UVA)
-
연락하다:
- James Ingersoll
- 전화번호: 434-982-1058
- 이메일: WFC5KC@uvahealth.org
-
수석 연구원:
- Todd Villines, MD
-
Fairfax, Virginia, 미국, 22031
- 아직 모집하지 않음
- Inova Health System
-
연락하다:
- Mahira Awan
- 전화번호: 571-472-8570
- 이메일: mahira.awan@inova.org
-
수석 연구원:
- Jared Spitz, MD
-
-
Wisconsin
-
Marshfield, Wisconsin, 미국, 54449
- 모병
- Marshfield Clinical Research Institute
-
연락하다:
- Kelly Scheffen
- 전화번호: 715-221-7285
- 이메일: preempt@marshfieldresearch.org
-
수석 연구원:
- Jeff VanWormer
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Women aged 40-60 years; Men aged 30-50 years
- Willing and able to provide informed consent and comply with study procedures
- Smart phone user
- Use of highly effective contraception by females with reproductive potential.
- CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
- Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab
Exclusion Criteria:
- Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
- Current symptoms thought to be from CAD
- PREVENT ASCVD 10-year risk ≥5% (if known)
- Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
- LDL-C ≥190mg/dL (most recent, if known)
- HIV (if known)
- Severe liver disease or untreated Hepatitis C infection (if known)
- Pregnancy, lactation or intending to become pregnant during the study period of 2 years
- eGFR <45mL/min/1.73m2 (if known)
- AST or ALT >1.5x the upper limit of normal (if known)
- BMI>40kg/m2 or unable to have a CCTA scan for any reason
- Allergy to iodinated intravenous contrast or other contraindication to CCTA
- Current or previous use of lipid lowering therapy or colchicine
- Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
- Systemic cancer undergoing active treatment
- PREVENT ASCVD 10-year risk ≥5%
- eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
- Hemoglobin A1c ≥6.5% per baseline labs
- LDL-C ≥190mg/dL per baseline labs
- Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
- Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
- Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: rosuvastatin 20mg plus colchicine-matched placebo
statin plus placebo (two pills once daily) |
Statin
다른 이름들:
Placebo, non-active, drug-matched |
|
실험적: colchicine 0.5mg plus rosuvastatin-matched placebo
anti-inflammatory plus placebo (two pills once daily) |
Placebo, non-active, drug-matched Anti-inflammatory
다른 이름들:
|
|
실험적: rosuvastatin 20mg plus colchicine 0.5mg
statin plus anti-inflammatory (two pills once daily) |
Statin
다른 이름들:
Anti-inflammatory
다른 이름들:
|
|
위약 비교기: placebo plus placebo
Placebo and placebo (two pills once daily) |
Placebo, non-active, drug-matched |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
기간: 2 years
|
Plaque volume in mm3 in each group |
2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
LDL-C(저밀도 지단백 콜레스테롤) 변화
기간: 기준 시점부터 2년까지
|
기준 시점부터 2년까지
|
|
|
비 HDL-C(고밀도 지단백 콜레스테롤) 변화
기간: 기준선부터 2년까지
|
기준선부터 2년까지
|
|
|
Number of participants with Drug Discontinuation
기간: Up to 2 years
|
Drug Tolerability outcome |
Up to 2 years
|
|
Overall drug treatment adherence
기간: Up to 2 years
|
Number of days on study drugs |
Up to 2 years
|
|
Safety events of special interest
기간: Up to 2 years
|
Number of safety events of special interest per group |
Up to 2 years
|
|
Total plaque volume
기간: Up to 2 years
|
Plaque volume in mm3 per group |
Up to 2 years
|
|
Low-attenuation plaque volume
기간: Up to 2 years
|
Low attenuated plaque volume in mm3 per group |
Up to 2 years
|
|
Calcified plaque volume
기간: Up to 2 years
|
Calcified plaque volume in mm3 per group |
Up to 2 years
|
|
Number of participants with stenosis
기간: Up to 2 years
|
Number of participants with stenosis per group |
Up to 2 years
|
|
Segment involvement score
기간: Up to 2 years
|
Average score per group |
Up to 2 years
|
|
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
기간: Up to 2 years
|
Number of participants with each plaque composition description per group |
Up to 2 years
|
|
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
기간: Up to 2 years
|
Number of participants with each plaque feature (high-risk) per group |
Up to 2 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Pro00118744
- UG3HL181434 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .